SLC5A2 and heart failure: Hazard reductions were also observed for the modified cardiovascular composite (HR 0.81, 95% CI 0.74-0.88) and heart failure (HR 0.78, 95% CI 0.68-0.89).<h4>Conclusions</h4>In this large real-world cohort, combination therapy with SGLT-2 inhibitors and GLP-1 RAs was associated with a lower hazard of all-cause mortality, while most secondary cardiorenal outcomes showed generally favourable but imprecise estimates.